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IFN-a AND IFN-t HAVE DIFFERENT REGULATORY EFFECTS ON IL-4-INDUCED 
MEMBRANE EXPRESSION OF FceRIIb AND RELEASE OF SOLUBLE FceRIIb BY 
HUMAN MONOCYTES1
AN JE A. TE VELDE,2* FRANÇOISE ROUSSET/ CATHERINE PERONNE,+ JAN E. DE VRIES,3t and
CARL G. FIGDOR*
From the *Division of Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huts, 1066 CX Amsterdam,
The Netherlands; and  *Unicet, Dardilly, France
We used highly purified human monocytes to 
study the regulation of cell surface and secretion of 
the low affinity FcR for IgE (FceRIIb). IL-4 induces 
FceRIIb expression and soluble FceRIIb release in a 
dose-dependent manner. Significant levels of 
FceRIIb expression were obtained after 12 h of in­
cubation with IL-4 and maximal expression was ob­
served between 24 to 48 h after which the expres­
sion declined. Surface expression was followed by 
secretion of soluble FceRIIb which reached maximal 
levels after 3 to 4 days of incubation and which 
remained constant throughout 7 days of culture. 
Induction of FceRIIb expression by IL-4 was com­
pletely blocked by anti-IL-4 antibodies. Further­
more, IL-la, IL-2, IL-5, granulocyte-macrophage- 
CSF, IFN-a, IFN-y, low m.w. BCGF and also LPS all 
failed to induce FceRIIb expression, demonstrating 
the specificity of the induction. FceRIIb membrane 
expression induced by IL-4 was reduced in the pres­
ence of IFN-7 and IFN-a. Strong inhibition of IL-4- 
induced FceRIIb expression was observed at IFN-a 
concentrations of 450 U/ml (80%)t and 100 U/ml of 
IFN-7 reduced IL-4-induced FceRIIb expression by 
70%. Interestingly, soluble FceRIIb release was 
strongly inhibited by IFN-a. In contrast, IFN-7 did 
not affect soluble FceRIIb release, suggesting that 
reduced membrane expression of FceRIIb observed 
in the presence of IFN-7 does not reflect inhibition 
of FceRIIb expression but may represent enhanced 
cleavage or reduced anchoring in the membrane of 
FceRIIb. Finally, IL-5 that has been shown to en­
hance IL-4-induced FceRII on B cells does not en­
hance significantly IL-4-induced FceRIIb membrane 
expression or subsequent soluble FceRIIb release by 
monocytes. Taken together these results show that 
IFN-a and IFN-7 have different regulatory effects on 
IL-4-induced FceRIIb membrane expression and sol­
uble FceRIIb release by human monocytes.
Human rIL-4 has pleiotropic effects (1). IL-4 acts as a
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growth factor for activated T cells, thymocytes, NK cells, 
and B cells (2» 3). It can enhance specific CTL activity (4), 
but suppresses IL-2-induced lymphokine-activated killer 
cell activity (4, 5). IL-4 also induces the expression of the 
FceRII,4 that was found to represent the B cell activation 
marker CD23 and enhances the expression of class II 
MHC Ag both on normal and malignant B cells (6-8),
IL-4 promotes the subsequent release of a soluble form 
of CD23 from B cells (9). Recently B cells were found to 
express two species of low affinity receptors for IgE 
FceRIIa and FceRIIb. FceRIIa is constitutively expressed 
on normal B cells and B cell lines, whereas FceRIIb is 
inducible by IL-4 on B cells, monocytes, and eosinophils 
(10).
Whereas IL-4 induces IgE synthesis by normal B cells 
(11-13), this induction requires both CD4+ T cells and 
monocytes (11, 14), Binding of IgE to FceRIIb expressed 
by monocytes and macrophages (15), followed by binding 
of allergen to these receptors results in macrophage ac­
tivation (16, 17). Interestingly, induction of FceRIIa and - 
b expression on human B cells and IgE synthesis by IL-4 
was completely blocked by IFN-7 and IFN-a, but induced 
by IL-5 (7, 11-14). In addition IFN-7 administration in 
vivo inhibits murine IgE production (18, 19). These re­
sults indicate that IFN-7 , IFN-a, and IL-5 together act as 
regulators of IL-4-induced IgE responses of B cells.
In a previous study (20) we reported that IL-4 enhances 
the expression of the LFA-1 family molecules CR3 and 
p i50,95 and class II MHC Ag on human monocytes. 
During these studies we noted that IL-4 also induces 
expression of FceRIIb. This observation prompted us to 
investigate the effects of IL-4 and the regulation by IFN- 
at IFN-7 , and IL-5 of IL-4-induced FceRIIb expression and 
subsequent soluble FceRIIb release from human mono­
cytes. In our study it is demonstrated that IL-4 induces a 
strong induction of FceRIIb that subsequently is released 
in its soluble form. In addition it is shown that IFN-a and 
IFN-y have different regulatory effects on IL-4-induced 
FceRIIb membrane expression and soluble FceRIIb re­
lease, whereas IL-5 was ineffective.
MATERIALS AND METHODS
Isolation of monocytes. Human peripheral blood monocytes were 
isolated from 500 ml blood of normal human donors, as described 
previously (21, 22). The mononuclear cells were separated by density 
centrifugation with a blood component separator, followed by frac-
4 Abbreviations used in this paper: FcfRII, low affinity receptor for IgE; 
BCGF, B cell growth factor; GM-CSF, granulocyte macrophage-CSF; HSA, 
human serum albumin.
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tionation into lymphocytes and monocytes by centrifugal élutriation. 
The monocyte preparation was more than 95% pure, as judged by 
nonspecific esterase staining and contained more than 98% viable 
cells. Contamination with lymphocytes and granulocytes was always 
less than 2  and 3%, respectively. We reported previously that mono­
cytes isolated as described here, are not activated by the isolation 
procedure (23). Their expression of class II MHC molecules and H20 2 
production is very low as compared to that of monocytes that were 
allowed to adhere to plastic surfaces for 1 h at 37°C and 5% C02 
(Table I}.
Monocyte culture. Monocytes were cultured in Yssel’s medium 
(24) containing HSA and supplemented with 2% autologous heat- 
inactivated serum. The culture medium was found to be endotoxin- 
free (defined as less than 0 . 2  ng/ml of endotoxin, as quantified by 
the Limulus amebocyte lysate assay). Monocytes were incubated in 
a concentration of 4.106 cells/ml at 37°C, 5% C02, and 1 0 0 % humid­
ity in Teflon bags (Jansen MNL, St. Niklaas, Belgium). Monocytes 
were harvested after culture for x days, washed and resuspended in 
PBS containing 0.5% HSA and 0.02% sodium azide and kept on ice 
until testing. The viability by Trypan blue exclusion exceeded 90%. 
There was no difference in the number of cells that were recovered 
after culturing in the presence of different recombinant factors.
Lymphokines. rIL-4 was obtained as a purified protein from 
supernatants of L cells transfected with the cDNA (sp. act. 107 U/ 
mg), kindly provided by Dr. S. Nagabhushan (Schering-Plough Cor­
poration, Bloomfield, NY). One unit of IL-4 was defined as the con­
centration of IL-4 resulting in half maximal proliferation of PHA 
activated T lymphoblasts (25). Human rGM-CSF (sp. act. 107 U/mg), 
human rIFN- 7 (sp. act. 107 U/mg) and human rIFN-a: were kindly 
provided by Dr s. P. Trotta and S. Nagabhushan (Schering-Plough 
Corporation). Human rIL-2 and rIL-l-a were kindly provided by Drs. 
R. Kastelein and G. Zurawski, respectively (DNAX Research Insti­
tute, Palo Alto, CA). IL-5 was tested in the form of a supernatant of 
Cos-7 cells transfected with the pcD vector containing the cloned 
human IL-5 cDNA (26). Mock transfection supernatants (mock) of 
Cos-7 cells transfected with the pcD vector but not containing the 
DNA encoding IL-4, were used as controls, both kindly provided by 
Dr. N. Aral (DNAX Research Institute). LPS B (Bscherichia. coli 
0127:B8) was obtained from Difco Laboratories (Detroit, MÏ). A com­
mercial preparation of low m.w. B cell growth factor was obtained 
from Cellular Products Inc. (Buffalo, NY) and used at 10% v/v. The 
polyclonal rabbit anti-IL-4 antiserum that blocks the biologic activity 
of IL-4 has been described previously (27). This antibody is specific 
for IL-4 and blocks the IL-4-induced proliferation of T cells (2), B 
cells (27), and IL-4-induced IgE synthesis (11, 12).
Detection of surface membrane determinants. The expression 
of class II MHC Ag on freshly isolated and 1 h adherent monocytes 
was determined by binding of the mAb 95/13 (anti-HLA-DR/DP; 
IgG2a) (28), provided by Dr. S. Ferrone, Medical College, Valhalla» 
NY. The expression of FceRIIb on freshly isolated and cultured 
monocytes was determined by the binding of the FceRII/CD23-spe- 
cific mAb 25 (IgGl) (29). Isotype matched mouse IgGl and IgG2a 
antibodies, which did not react with monocytes directed against 
idiotypic determinants on B cell lymphoma, were used as controls 
(30).
Immunofluorescence tests were carried out by incubating the 
monocytes with mAb (in PBS containing 0.5% HSA and 0.02% azide) 
for 30 min at 0°C. After washing three times with PBS/HSA/azide, 
the monocytes were incubated with FITC-labeled goat F(ab) 2 anti­
mouse IgG antibody (Nordic, Tilburg, The Netherlands) for 30 m in at 
0°C. Subsequently, the cells were washed, suspended in PBS/HSA/ 
azide and analyzed with a FACS IV or a FACScan (Becton Dickinson, 
Mountain View, CA). Data are expressed as mean fluorescence in­
tensity (arbitrary units) as measured on 4 decades logarithmic am- 
plifyer (FACScan) and percentage positive cells.
Detection of soluble FceRIIb. FceRIIb in supernatants of monocyte 
cultures was detected in a sandwich ELISA in which the mAb 25
TABLE I
Effect of adherence to plastic surfaces on class II MHC Ag expression
and H202 production by monocytesa
Treatment MHC Class II Ag Expression H20 2 Production
0°C 50b 0.4C
37°C, 60 min adherence 125 1 . 2
a Monocytes were allowed to adhere to plastic culture plates for 60 min 
at 37°C and 5% C02 or kept on ice.
b Data expressed as mean fluorescence intensity. Negative control val­
ues using isotype specific mAb were 2 . 0  and 2.5 for 0 and 37°C, respec­
tively.
c Data expressed as nmole H202. Production of H20 2 of 5  x 10s cells in 
10 min after PMA stimulation was determined as described previously 
(40).
and H I07, that are directed against different epitopes on FceRII were 
used (31). Briefly, ELISA plates were coated with 50 /¿I of mAb 25 (2 
Mg/ml). Nonspecific binding sites were blocked with 10 mM PBS, pH 
7.2, containing 2% BSA and 0.05% Tween 20. The soluble FceRIIb 
containing supernatants were incubated at 4°C for 4 h, whereas the 
plates were washed and incubated with 50 ¡x\ of alkaline phosphatase 
conjugated H107 mAb (1.3 jug/ml) at 4°C for 4 h. The reaction was 
visualized by adding 1 0 0  ¿¿1 of the enzyme substrate solution p- 
nitrophenyl phosphate dissolved in diethanolamine. After incuba­
tion at 37°C for 2 h the plates were read in an ELISA reader. The 
standard curve for soluble FceRIIb was determined by using affinity 
purified soluble rFceRII kindly provided by Dr. J. Yodoi (Kyoto Uni­
versity Medical School, Kyoto, Japan). The sensitivity of this ELISA 
is 20 pg soluble FceRII/ml (31).
RESULTS
IL-4 induces FceRIIb on human monocytes. We dem­
onstrated previously that monocytes, isolated as de­
scribed here, do not become activated by the isolation 
procedure (23). These monocytes provided an excellent 
source to study the induction of activation markers by 
IL-4. Freshly isolated monocytes and monocytes cultured 
in the absence of IL-4 do not express FceRIIb. However, 
monocytes express FceRIIb Ag in a dose-dependent fash- 
ion after 40 h of incubation in the presence of IL-4 (Fig. 
1 A}. Significant FceRIIb expression was already induced 
at IL-4 concentrations of 10 U/ml, whereas maximal 
induction of FceRIIb expression was observed at 50 to 
100 U/ml. Similar induction of soluble FceRIIb was de­
tected in the supernatant of monocytes cultured with IL- 
4 (Fig. IB). IL-4 does not cause a general nonspecific 
induction of Ag on the cell surface of monocytes because 
relevant control antibodies, which bind to the monocyte 
surface, such as leukocyte function-associated Ag 1, are 
not induced in the presence of IL-4 (20), Kinetics of 
induction of FceRIIb expression showed that significant 
FceRIIb expression was induced after 12 h of incubation 
with IL-4, whereas maximal expression was observed 
between 24 and 48 h of incubation (Fig. 2). Incubation 
for more than 48 h resulted in a decrease in the expres­
sion of FceRIIb, whereas expression was completely lost 
at day 5. These data indicate that induction of FceRIIb 
expression by IL-4 is transient. This notion was sup­
ported by the finding that renewed addition of IL-4 (100 
U/ml) on day 4 of the culture had no effect on FceRIIb 
expression (results not shown). Furthermore, our data 
indicate that IL-4 not only induces membrane expression 
of FceRIIb, but also results in the subsequent release of 
relatively large quantities of soluble FceRIIb (Fig. 2) reach­
ing optimal levels after 3 to 4 days of incubation, which 
remained unchanged during the next 3 days of culture.
Induction of FceRIIb expression by IL-4 (100 U/ml) was 
completely blocked by the anti-IL-4 antiserum, demon­
strating the specificity of the induction (Fig. 3A). This 
notion was supported by the finding that neither IL-la, 
IL-2, IL-5, GM-CSF, IFN-y, IFN-a, c-BCGF, or LPS were 
able to induce FceRIIb expression (Fig. 3B), after 20 h of 
culture. Longer incubation periods (48 to 72 h) also did 
not induce FceRIIb expression of cultures negative for 
FceRIIb on 20 h (not shown). This indicates that factors 
known to induce monocyte activation (IL-la, GM-CSF, 
IFN-a, IFN-y, and LPS) are not involved in FceRIIb expres­
sion.
IL-4-induced membrane expression oj FceRIIb is re­
duced by IFN-y and IFN-a. We previously demonstrated 
that IFN- 7  and IFN-a can act as antagonists of IL-4. IFN- 
y has been shown to block IL-4-induced FceRIIb expres-
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Figure 1. IL-4 Induces the expression of FceRIIb (A) and release of 
soluble FceRIIb (JB) from human monocytes. The cells were cultured for 
40 h with increasing concentrations of IL-4 as indicated [0, 1, 10, 50, 
and 100 U). FceRIIb was determined after subsequent staining with the 
FceRlI-specific mAb 25 or mouse IgGl control mAb and GAM F(ab)a FITC. 
Negative control values for all cultures were identical and are represented 
by the shaded area. The fluorescence Intensity of 5000 cells was deter­
mined with a FACScan. Soluble FceRIIb present in the culture superna­
tant was detected with a sandwich ELISA described in Materials and 
Methods. Values represent one representative experiment of four. SD did 
not exceed 1 0 % of triplicate determinations.
sion on normal and malignant B cells (7, 8 ) and both IFN- 
a and IFN-y blocked IL-4-induced IgE production by nor­
mal B cells (11-14). Fluorescence studies indicated that 
in the presence of IFN-y, IL-4 failed to induce membrane 
expression of FceRIIb on human monocytes (Fig. 4A). The 
addition of 100 U/ml of IFN-y resulted in a marked re­
duction of FceRIIb membrane expression (70%), whereas 
in the presence of 12.5 U/ml of IFN-y FceRIIb expression 
was still significantly lower as compared to control cul­
tures, as judged by both the percentage of FceRIIb* mono­
cytes and by membrane fluorescence intensity values. 
Strong inhibitory effects were also observed with IFN-a, 
IFN-a added at concentrations of 50 U/ml already inhib­
ited membrane FceRIIb expression by more than 50% 
(Fig. 4B). Eighty percent suppression was observed at 
450 U/ml. The IL-4-induced expression of HLA-DR and 
CR3 was not suppressed by addition of IFN-a? or IFN-y 
(results not shown). These results indicate that both 1FN- 
a and IFN-y specifically reduce IL-4-induced FceRIIb 
membrane expression of human monocytes.
IL-4-induced release of soluble FceRIIb is blocked by
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Figures. Time course of IL-4-(100 U/ml) induced FceRIIb expression 
and soluble FceRIIb release from human monocytes. After culture the 
percentage FceRIIb* cells and the soluble FceRIIb in the culture superna* 
tant were determined as described in the legend of Figure 1 . Negative 
control values did not exceed 2% positive cells. Values represent one 
representative experiment of three. SD did not exceed 10% of triplicate 
determinations.
IFN-a but not by IFN-y. Although at IFN-y concentrations 
of 100 to 200 U/ml no detection of IL-4-induced FceRIIb 
membrane expression was observed, no significant in­
hibitory effects on IL-4-induced soluble FceRIIb release 
in the culture medium were shown (Figs. 5B and 6A), In 
contrast, IFN-a efficiently blocked the release of soluble 
FceRIIb (Fig. 5A). Concentrations of 50 U/ml already 
resulted in 50% inhibition, whereas FceRIIb release was 
blocked for 80% at 450 U/ml of IFN-<*. In addition, kinetic 
studies indicated that IFN-y tested at 100, 25, and 5 U/ 
ml failed to block IL-4-induced soluble FceRIIb release 
(Fig. 6A}t whereas IL-4-induced FceRIIb membrane 
expression on day 2 was reduced in a dose-dependent 
fashion (Fig. 6B). The reduction of FceRIIb membrane 
expression in the presence of IFN-y varied from 45 to 
71% for six different donors tested (mean 59 ± 12.5). 
IFN-y alone did not induce FceRIIb membrane expression 
(Fig. 3B and 6B) and subsequent soluble FceRIIb release 
in the culture medium (Fig. 6A). In conclusion, these data 
indicate that in the presence of IFN-a and IFN-y a reduced 
IL-4-induced FceRIIb membrane expression was ob­
served, whereas only IFN-a, and not IFN-y significantly 
blocked soluble FceRIIb release from human monocytes.
IL-5 does not affect IL-4-induced FceRIIb expression 
and soluble FceRIIb release. Inasmuch as IL-5 has been 
shown to enhance IL-4-induced FceRII membrane expres­
sion and release of soluble FceRII by normal B cells (13), 
we were interested in the effects of IL-5 on FceRIIb 
expression and secretion by monocytes. Monocytes were 
incubated with IL-4 in combination with various concen­
trations of IL-5. In Figure 7A it is shown that IL-5, which 
in itself is ineffective (Fig. 3B), did not enhance IL-4- 
induced FceRIIb surface expression significantly. In ad­
dition no effect of IL-5 on IL-4-induced soluble FceRIIb 
release was observed (Fig. 7B). Taken together, these 
data indicate that IL-5 has differential effects on IL-4- 
induced FceRII expression on B cells and FceRIIb expres­
sion on monocytes.
DISCUSSION
Recently we demonstrated that IL-4 induced the 
expression of class II MHC Ag and CR3 and p i50,95 on
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350
Figure 3. Specificity of the induction of FceRIIb by IL-4. 
A, Induction of FccRIIb expression is completely blocked by 
the anti-IL-4 antiserum. The left interrupted line repre­
sents the negative control using mouse IgG control mAb. 
The fluorescence intensity was determined as described in 
the legend of Figure 1. B, Various other cytokines and LPS 
do not induce FceRIIb expression on monocytes after 20 h 
of culture. FceRIIb expression was determined as described 
in the legend of Figure 1. Fluorescence intensity of more 
than 10,000 cells was determined with the FACS IV. One 
representative experiment of three is shown.
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human monocytes (20), These changes in phenotype 
were accompanied by the induction of macrophage mor­
phology and inhibition of IL-1 (3 and TNF-a synthesis (20, 
32).5
In our study we demonstrate that IL-4 induces the 
expression of FceRIIb and subsequent release of soluble
5 Te Velde, A. A., R. J. F. Huijbens, C. Heije, J, E. de Vries, and C. G. 
Figdor. 1989. Interleukin-4 inhibits secretion of interleukin-1/3 and tumor 
necrosis factor and interleukin-6 by human monocytes. SubmittedJor 
publication.
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FceRIIb on normal highly purified human monocytes that 
were not activated by the isolation procedure (23) (Table 
I). The monocyte preparations were more than 95% pure. 
Contaminating cells that mainly consisted of granulo­
cytes and lymphocytes were not involved in expression 
or secretion of FceRIIb, because addition of various num­
bers of lymphocytes and granulocytes (up to 1 0%) did not 
affect the expression of FceRIIb by monocytes (results 
not shown), Induction of FceRIIb expression on mono-
3056 EFFECT OF CYTOKINES ON FceRIIb EXPRESSION AND sFceRIIb RELEASE
30 -
&
C/D
CV
V
0^
§
I!
20 -
10 -
E5
0 -  ■
12
8
>
m3♦
(✓3
a
$
UIFN Y
u. 30 -
V.
C
too
c
<DOyj
Ko
cri1)
10 -
0
100
B
- 90
- 80
- 70
-60
-50
- 40
- 30
" *  20
-  10
</>
T
0
T-
50
<oo
>■£i
C/J
O
cx
$
0
150 450
U IFN  a
Figure 4. IFN-y (A) and IFN-a (B} inhibit the induction of FceRIIb 
membrane expression on human monocytes by IL-4. Monocytes were 
cultured for 40 h with 100 U IL-4/ml and with increasing concentrations 
of IFN-y or IFN-a. Mean fluorescence intensity and percentage positive 
cells were determined as described in the legend of Figure 1. Negative 
control values were always lower than 3 (mean fluorescence intensity) 
and less than 2% positive cells. Data of one representative experiment of 
three are shown.
cytes seems to be an unique property of IL-4, because a 
large number of cytokines (IL-la, IL-2, IL-5, GM-CSF, 
IFN-y, IFN-a, and low m.w. BCGF) were ineffective de­
spite the fact that many of these factors have been shown 
to activate monocytes, Furthermore, LPS, which is a 
strong monocyte activator failed to induce FceRIIb expres­
sion. Collectively, these data indicate that IL-4 can spe­
cifically activate monocytes to express FceRIIb, because 
monocytes cultured in the absence of IL-4 remained 
FceRIIb“.
IL-4 did not only induce the induction of membrane 
FceRIIb, but also the subsequent release of soluble 
FceRIIb. Disappearance of FceRIIb at the membrane cor­
related with the kinetics of soluble FceRIIb release. Sol­
uble FceRIIb levels increased strongly after 72 h of incu­
bation and remained stable from day 4 to 7, indicating 
that there is no further accumulation of soluble FceRIIb 
in the supernatants when FceRIIb membrane expression 
is low or absent. Therefore the disappearance of mem­
brane FceRIIb may reflect release of soluble FceRII. How-
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Figured. IFN-a (A) but not IFN-y (£) clearly inhibits the induction of 
the release of soluble FceRIIb from human monocytes by IL-4. Monocytes 
were cultured with 100 U IL-4/ml and increasing concentrations of IFN- 
y or IFN-a for 40 h. Soluble FceRIIb in the culture supernatant was 
detected in a sandwich ELISA, as described In Materials and Methods. 
Data are expressed as means ±SD. One representative experiment of 
three is shown.
ever, a continuous turnover of FceRIIb in the membrane 
together with a degradation or use of soluble FceRIIb can 
not be excluded. Finally, the relatively rapid loss of mem­
brane-bound FceRIIb may be due to the inactivation of 
the gene as has already been suggested by Delespesse et 
al. (33) and that may be compatible with the observation 
that renewed addition of IL-4 was ineffective. We dem­
onstrated previously that IL-4 induced FceRII expression 
on normal and malignant B cells (7, 8 ) and that this IL-4 
effect was blocked by IFN-y (7, 8 , 11-14), but enhanced 
by IL-5 (13). Here it is shown that both IFN-y and IFN-a 
also reduced IL-4-induced FceRIIb membrane expression 
on monocytes in a dose-dependent fashion. These data 
are in contrast to those of Vercelli et al. (34), who dem­
onstrated that FceRIIb membrane expression on mono­
cytes induced by IL-4 could not be blocked by IFN-y. In 
addition, Delespesse et al. (33) reported that IFN-y en­
hanced not only the production of soluble FceRIIb by 
monocytes and by U937 cells but also induced FceRIIb 
mRNA expression in these cells. IFN-y (100 U/ml), which 
induced class II MHC expression in our experiments (not 
shown), failed to induce FceRIIb membrane expression. 
These discrepancies may be related to the different mon­
ocyte isolation procedures used by Vercelli et al. (34) and
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Figured. Kinetics of the effect of IFN-y on IL-4-induced soluble 
FceRIIb release (A) and FceRIIb membrane expression (B). The monocytes 
were cultured with 100 U IL-4/ml (■), 100 U IFN-y/ml (•), 100 U IL-4 + 5 
U (□), 25 U (O), or 100 U (A) IFN-y/ml. Soluble FceRIIb in the culture 
medium was detected by means of a sandwich ELISA, as described in 
Materials and Methods and FceRIIb membrane expression was deter­
mined using a FACScan as described in the legend of Figure 1. The mFI 
of negative controls of all cultures ranged from 3 to 5. Data of one 
representative experiment of three are shown. SD of triplicate determi­
nations did not exceed 10%.
Delespesse et al. (33). Adherence of monocytes to plastic 
surfaces results in activation of these cells and addition 
of IFN-y to these activated monocytes may act as a second 
activation signal resulting in FceRIIb induction. In addi­
tion, other cell types (NK cells) have the capacity to adhere 
to plastic surfaces (35).
Surprisingly, IFN-y had no significant inhibitory ef­
fects on the secretion of IL-4-induced soluble FceRIIb, 
whereas IFN-a that prevented IL-4-induced membrane 
expression of FceRIIb more efficiently than IFN-y, inhib­
ited both surface expression and secretion of soluble 
FceRIIb. These results indicate that IFN-a and IFN-y have 
different regulatory effects on IL-4-induced FceRIIb re­
lease. Furthermore, if soluble FceRIIb release is preceded 
by membrane expression of FceRIIb, it could be that IFN- 
y induces activation of proteases which via an autopro- 
teolytic process immediately cleave the 25-kDa soluble 
FceRIIb fragment from the 45-kDa surface FceRIIb form
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Figure 7. IL-5 has no effect on the IL-4-induced FceRIIb expression 
(A) and soluble FceRIIb release (B) from human monocytes. Monocytes 
were cultured for 40 h with increasing concentrations of IL-4 with or 
without addition of 0.1 or 0,5% IL-5 cos 7 supernatant. Percentage 
positive FcfRIIb cells and soluble FceRIIb in the culture supernatant were 
determined as described in the legend of Figure 1. Values of one repre­
sentative experiment are shown. SD of three samples did not exceed 10%.
(33). This implies that we do not deal with inhibition of 
IL-4-induced membrane expression of FceRIIb by IFN-y, 
but with enhanced autoproteolytic cleavage induced by 
IFN-y. Inasmuch as our anti-FceRII mAb reacts with de­
terminants on the 25-kDa soluble fragment of FceRII (9), 
this results in no or strongly reduced levels of FceRIIb 
expression on the membrane. Another explanation might 
be that under the influence of autoproteolytic activity 
induced by IFN-y, the truncated 25-kDa FceRIIb is already 
cleaved off before the 45-kDa FceRIIb is anchored in the 
monocyte membrane, IL-5, which enhanced IL-4-induced 
FceRIIb expression, soluble FceRIIb release and IgE syn­
thesis by normal B cells (13, 14), did not augment IL-4- 
induced FceRIIb expression and soluble FceRIIb release 
from monocytes. IL-5 was also ineffective when tested 
alone. Inasmuch as B cells express two species of low 
affinity receptors for IgE FceRIIa and FceRIIb it is pres­
ently unclear whether the enhanced FceRIIb expression 
observed in the presence of IL-4 plus IL-5 on B cells is 
related to up regulation of only FceRIIa expression.
The precise function of FceRIIb and monocyte-derived 
soluble FceRIIb remains to be determined, but soluble 
FceRII, purified from supernatants of EBV-transformed
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B cell lines, has been shown to act as a BCGF (36). 
However, soluble FceRII derived from EBV-transformed 
B cell lines, enhances ongoing IgE production by B cells 
from allergic individuals (37). Consistently with this ob­
servation it has been reported that FceRII fractionated 
from B cell line culture supernatants and soluble rFceRII 
enhanced IgE production by B cells from healthy individ­
uals induced by IL-4 (13, 38). Inasmuch as we demon­
strated that optimal induction of IgE synthesis by IL-4 
requires the presence of CD4+ T cells» soluble FceRII, and 
monocytes (10, 13, 14), our results suggest that mono­
cytes might contribute to the regulation of the human 
IgE response by secretion of FceRIIb. This notion is sup­
ported by the finding that IFN-a which inhibits IL-4- 
induced IgE production in vitro, also blocks FceRIIb mem­
brane expression and subsequent soluble FceRIIb release 
by B cells and monocytes. However, it is noteworthy that 
IFN-y, despite the fact that it efficiently blocked IL-4- 
induced IgE production in vitro, did not affect the secre­
tion of soluble FceRIIb by monocytes. These data suggest 
that expression and secretion of FceRIIb are differentially 
regulated. However, IFN-y strongly blocks expression and 
secretion of soluble FceRII by B cells (33) or mononuclear 
cell populations depleted of adherent cells» indicating 
that if soluble FceRII is indeed associated with IgE syn­
thesis, the inhibition of IgE synthesis by IFN-y occurs via 
different mechanisms. Recently, Yokota et al. (10) dem­
onstrated that FceRIIb mRNA was expressed in PBL from 
an atopic donor with high serum levels of IgE. These 
data, in combination with the observation that IL-4 in­
duced FceRII on B cells (6, 7) further supports the notion 
that in addition to IL-4, which induces IgE production 
(11, 14), FceRIIb may be associated with the regulation of 
IgE synthesis. Inasmuch as resting monocytes fail to 
express FceRIIb and FceRIIb expression is specifically 
induced by IL-4, it is interesting to note that alveolar 
macrophages of asthmatic patients probably express 
FceRIIb constitutively, because they were able to bind IgE 
(39). This binding of IgE resulted in mediator release, 
again indicating that both IL-4 and FceRIIb play an im­
portant role in the processes resulting in allergy.
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